Mazen Dimachkie

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Dr. Dimachkie received research grants or contracts or educational grants from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Dr. Dimachkie received research grants or contracts or educational grants from MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, The Myositis Association
    Date added: 
    01/06/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Dr. Dimachkie received research grants or contracts or educational grants from UCB Biopharma / RaPharma, Viromed/Healixmith & TMA.
    Date added: 
    01/06/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Dr. Dimachkie serves or recently served as a consultant for Amazentis, ArgenX, Catalyst, Cello, Covance/Labcorp, CSL-Behring, EcoR1, Janssen, Kezar, Momenta, NuFactor, Octapharma, RaPharma/UCB, Roivant Sciences Inc, RMS Medical, Sanofi Genzyme
    Date added: 
    01/06/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Dr. Dimachkie serves or recently served as a consultant for Shire Takeda, Scholar Rock, Spark Therapeutics, Third Rock and UCB Biopharma.
    Date added: 
    01/06/2022
Return to 45th Annual Carrell Krusen Neuromuscular Symposium (RP2302A)